Sunday, May 11

European Drugs Watchdog Finds Benefits Of Tysabri Continue To Outweigh Risks

The European Medicines Agency (EMA) has finalised a review of Tysabri (natalizumab) and the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by the JC virus.

The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the risk of developing PML increases after two years of use of Tysabri although this risk remains low.

It also stated, however, that the benefits of the medicine continue to outweigh its risks for patients with highly active relapsing-remitting multiple sclerosis, for whom there are few treatment options available.

As a result of the review, the Committee recommended a number of measures be put in place to ensure that patients and doctors are fully aware of the risks of PML. ....full report in Medical News Today